| The impact of COVID-19 and strategies for mitigation and suppression in low-and middle-income countries PGT Walker, C Whittaker, OJ Watson, M Baguelin, P Winskill, A Hamlet, ... Science, 2020 | 916 | 2020 |
| Accelerating the elimination of viral hepatitis: a Lancet Gastroenterology & Hepatology Commission GS Cooke, I Andrieux-Meyer, TL Applegate, R Atun, JR Burry, ... The lancet Gastroenterology & hepatology 4 (2), 135-184, 2019 | 474 | 2019 |
| Requirements for global elimination of hepatitis B: a modelling study S Nayagam, M Thursz, E Sicuri, L Conteh, S Wiktor, D Low-Beer, ... The Lancet Infectious Diseases 16 (12), 1399-1408, 2016 | 384 | 2016 |
| The gamma-glutamyl transpeptidase to platelet ratio (GPR) predicts significant liver fibrosis and cirrhosis in patients with chronic HBV infection in West Africa M Lemoine, Y Shimakawa, S Nayagam, M Khalil, P Suso, J Lloyd, ... Gut 65 (8), 1369-1376, 2016 | 375 | 2016 |
| Endoscopic ultrasound guided fine needle aspiration for the diagnosis of pancreatic cystic neoplasms: a meta-analysis GD Thornton, MJW McPhail, S Nayagam, MJ Hewitt, P Vlavianos, ... Pancreatology 13 (1), 48-57, 2013 | 297 | 2013 |
| Endoscopic ultrasound guided fine needle aspiration for the diagnosis of pancreatic cystic neoplasms: a meta-analysis GD Thornton, MJ McPhail, S Nayagam, MJ Hewitt, P Vlavianos, ... BMJ Publishing Group, 2012 | 297 | 2012 |
| Scaling up prevention and treatment towards the elimination of hepatitis C: a global mathematical model A Heffernan, GS Cooke, S Nayagam, M Thursz, TB Hallett The Lancet 393 (10178), 1319-1329, 2019 | 274 | 2019 |
| Adapting hospital capacity to meet changing demands during the COVID-19 pandemic R McCabe, N Schmit, P Christen, JC D’Aeth, A Løchen, D Rizmie, ... BMC medicine 18 (1), 1-12, 2020 | 207 | 2020 |
| Viral hepatitis in resource-limited countries and access to antiviral therapies: current and future challenges M Lemoine, S Nayagam, M Thursz Future virology 8 (4), 371-380, 2013 | 188 | 2013 |
| Acceptability and feasibility of a screen-and-treat programme for hepatitis B virus infection in The Gambia: the Prevention of Liver Fibrosis and Cancer in Africa (PROLIFICA) study M Lemoine, Y Shimakawa, R Njie, M Taal, G Ndow, I Chemin, S Ghosh, ... The Lancet Global Health 4 (8), e559-e567, 2016 | 161 | 2016 |
| Cost-effectiveness of community-based screening and treatment for chronic hepatitis B in The Gambia: an economic modelling analysis S Nayagam, L Conteh, E Sicuri, Y Shimakawa, P Suso, S Tamba, R Njie, ... The Lancet Global Health 4 (8), e568-e578, 2016 | 122 | 2016 |
| Food intake increases liver stiffness measurements and hampers reliable values in patients with chronic hepatitis B and healthy controls: the PROLIFICA experience in The Gambia M Lemoine, Y Shimakawa, R Njie, HF Njai, S Nayagam, M Khalil, ... Alimentary pharmacology & therapeutics 39 (2), 188-196, 2014 | 78 | 2014 |
| Development of a simple score based on HBeAg and ALT for selecting patients for HBV treatment in Africa Y Shimakawa, R Njie, G Ndow, M Vray, PS Mbaye, P Bonnard, R Sombié, ... Journal of hepatology 69 (4), 776-784, 2018 | 69 | 2018 |
| In-hospital mortality is associated with inflammatory response in NAFLD patients admitted for COVID-19 R Forlano, BH Mullish, SK Mukherjee, R Nathwani, C Harlow, P Crook, ... Plos one 15 (10), e0240400, 2020 | 62 | 2020 |
| Clinical characteristics and predictors of outcomes of hospitalized patients with COVID-19 in a multi-ethnic London NHS Trust: a retrospective cohort study PN Perez-Guzman, A Daunt, S Mukherjee, P Crook, R Forlano, MD Kont, ... Clin Infect Dis, 2020 | 55 | 2020 |
| Hepatitis B core-related antigen: an alternative to hepatitis B virus DNA to assess treatment eligibility in Africa Y Shimakawa, G Ndow, R Njie, HF Njai, K Takahashi, SMF Akbar, ... Clinical Infectious Diseases 70 (7), 1442-1452, 2020 | 52 | 2020 |
| Hepatitis B core-related antigen (HBcrAg): an alternative to HBV DNA to assess treatment eligibility in Africa Y Shimakawa, G Ndow, R Njie, HF Njai, K Takahashi, M Akbar, D Cohen, ... | 52* | 2019 |
| The global burden of chronic hepatitis B virus infection: comparison of country-level prevalence estimates from four research groups N Schmit, S Nayagam, MR Thursz, TB Hallett International Journal of Epidemiology, 2020 | 47 | 2020 |
| The investment case for hepatitis B and C in South Africa: adaptation and innovation in policy analysis for disease program scale-up R Hecht, L Hiebert, WC Spearman, MW Sonderup, T Guthrie, TB Hallett, ... Health policy and planning 33 (4), 528-538, 2018 | 45 | 2018 |
| Mother‐to‐child transmission of hepatitis B: What more needs to be done to eliminate it around the world? S Nayagam, Y Shimakawa, M Lemoine Journal of viral hepatitis 27 (4), 342-349, 2020 | 35 | 2020 |
